Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum

被引:33
|
作者
Subehan
Usia, Tepy
Kadota, Shigetoshi
Tezuka, Yasuhiro [1 ]
机构
[1] Toyama Univ, Inst Nat Med, Toyama 9300194, Japan
[2] Toyama Univ, 21st Century COE Program, Toyama 9300194, Japan
关键词
Piper nigrum; alkamides; cytochrome P450 2D6; CYP2D6; mechanism-based inhibition; drug-herb interaction;
D O I
10.1055/s-2006-931558
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Nineteen alkamides isolated from Piper nigrum L. were tested for their mechanism-based inhibition on human liver microsomal dextromethorphan O-demethylation activity, a prototype marker for cytochrome P450 2D6 (CYP2D6). All compounds increased their inhibitory activity with increasing preincubation time. Among them, 15 and 17 showed more than 50% decrease of the CYP2D6 residual activity after 20 min preincubation. Further investigations on 15 and 17 showed that the characteristic time and concentration-dependent inhibition, which required a catalytic step with NADPH, was not protected by nucleophiles, and was decreased by the presence of a competitive inhibitor. The kinetic. parameters for inactivation (k(inact) and k(I)) were 0.028 min(-1) and 0.23 mu M for 15 and 0.064 min(-1) and 0.71 mu M for 17, respectively, which were stronger than the known mechanism-based inhibitor, paroxetine (a positive control). Thus, 15 and 17 are potent mechanism-based inhibitors of CYP2D6.
引用
收藏
页码:527 / 532
页数:6
相关论文
共 50 条
  • [21] Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver
    Langenfeld, Elmar
    Zanger, Ulrich M.
    Jung, Klaus
    Meyer, Helmut E.
    Marcus, Katrin
    PROTEOMICS, 2009, 9 (09) : 2313 - 2323
  • [22] Interaction of delavirdine with human liver microsomal cytochrome P450: Inhibition of CYP2C9, CYP2C19, and CYP2D6
    Voorman, RL
    Payne, NA
    Wienkers, LC
    Hauer, MJ
    Sanders, PE
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (01) : 41 - 47
  • [23] Cytochrome P450 2D6 (CYP2D6) is decreased in patients with PPH: A potential mechanism for anorexigen-induced pulmonary hypertension
    Geraci, MW
    Cutrell, JD
    Moore, MD
    Tuder, RM
    Voelkel, NF
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A163 - A163
  • [24] The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients
    Topic, E
    Stefanovic, M
    Ivanisevic, AM
    Petrinovic, R
    Curcic, I
    CLINICA CHIMICA ACTA, 2000, 296 (1-2) : 101 - 109
  • [25] Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin
    Haritos, VS
    Ghabrial, H
    Ahokas, JT
    Ching, MS
    PHARMACOGENETICS, 2000, 10 (07): : 591 - 603
  • [26] Persistent mood disorders and cytochrome P450 2D6:: influence of the CYP2D6 gene duplication on the development of persistence
    Kawanishi, C
    Ågren, H
    Bertilsson, L
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (03) : 180 - 180
  • [27] Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    Ingelman-Sundberg, M
    PHARMACOGENOMICS JOURNAL, 2005, 5 (01): : 6 - 13
  • [28] Contributions of Ionic Interactions and Protein Dynamics to Cytochrome P450 2D6 (CYP2D6) Substrate and Inhibitor Binding
    Wang, An
    Stout, C. David
    Zhang, Qinghai
    Johnson, Eric F.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (08) : 5092 - 5104
  • [29] The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
    Chen, SQ
    Chou, WH
    Blouin, RA
    Mao, ZP
    Humphries, LL
    Meek, C
    Neill, JR
    Martin, WL
    Hays, LR
    Wedlund, PJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) : 522 - 534
  • [30] Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    M Ingelman-Sundberg
    The Pharmacogenomics Journal, 2005, 5 : 6 - 13